Picotamide is an antiplatelet drug that inhibits both thromboxane A2 (TXA2) receptors (Kd = 325 nM) and TXA2 synthase.[1] [2] It significantly inhibits basal and lipopolysaccharide-stimulated TXA2 synthesis by rat peritoneal macrophages when used at 0.5 mM.[3] Formulations containing picotamide have potential applications in the reduction of peripheral artery disease in patients with diabetes.[1]

Reference:
[1]. Celestini, A., and Violi, F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc. Health Risk Manag. 3(1), 93-98 (2008).
[2]. Modesti, P.A., Cecioni, I., Colella, A., et al. Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist. Br. J. Pharmacol. 112(1), 81-86 (1994).
[3]. Matera, G., Chisari, M., Altavilla, D., et al. Selective thromboxane synthetase inhibition by picotamide and effects on endotoxin-induced lethality. Proc. Soc. Exp. Biol. Med. 187(1), 58-61 (1988).